Safety and Preliminary Efficacy of MBS8(1V270) in Cancer Patients With Advanced Solid Tumours

The Phase I trial is evaluating safety, tolerability, pharmacokinetics and preliminary efficacy of MBS8(1V270) in subjects with advanced solid tumours. The trial is designed to provide data for further clinical development of MBS8(1V270)

Trial Details

NCT ID
NCT04855435
Phase
PHASE1
Sponsor
MonTa Biosciences ApS
Status
RECRUITING
Cancer Type
Melanoma
Interventions
  • MBS8(1V270)
  • MBS8(1V270) and pembrolizumab combination
Locations (sample)
  • Herlev, Denmark|55.72366,12.43998
  • Barcelona, Spain|41.38879,2.15899
  • Madrid, Spain|40.4165,-3.70256
  • Madrid, Spain|40.4165,-3.70256
  • Valencia, Spain|39.47391,-0.37966

Key Eligibility Criteria

  • Male or female aged ≥18 years.
  • Diagnosis of a histologically or cytologically confirmed solid tumour that was advanced and with progression. No standard treatment existed, or the…
  • Tumour lesion(s) accessible to serial biopsies.
  • Was willing and able to comply with scheduled visits, treatment schedule, laboratory tests, and tumour biopsies. Mandatory Baseline and on-treatmen…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Melanoma Trials on Trialify →